Trial Profile
An Open Label, Single-Center Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2018
Price :
$35
*
At a glance
- Drugs Armodafinil (Primary)
- Indications Dementia; Lewy body disease
- Focus Therapeutic Use
- 21 Apr 2016 Results (n=20) presented at the 68th Annual Meeting of the American Academy of Neurology.
- 21 Apr 2016 Results assessing neuropsychiatric morbidity presented at the 68th Annual Meeting of the American Academy of Neurology
- 02 May 2012 Actual end date (March 2012) added as reported by ClinicalTrials.gov.